What is Ozanimod? Quick Facts about New IBD Treatment

What is Ozanimod? Quick Facts about New IBD Treatment

Ozanimod is a new medication for chronic inflammatory diseases currently in Phase 3 clinical trials as an IBD treatment.

Quick facts about Ozanimod

Developed by: The Scripps Research Institute, partnered with Celgene
Code: RPC1063
Conditions: various autoimmune conditions; multiple sclerosis, Crohn’s disease, ulcerative colitis
Drug type: sphingosine 1-phosphate 1 (S1PR1) receptor antagonist
Administration: trials have examined both oral and injected doses
How It Works: Ozanimod inhibits the receptor of a protein called S1PR1. Among other functions, S1PR1 regulates the growth and transport of lymphocytes (immune cells). By inhibiting S1PR1, Ozanimod decreases lymphocytes in the gastrointestinal tract, modifying the immune response.

Ozanimod Research

For IBD patients who have experienced failure with anti-TNF treatments such as Humira, Simponi, Cimzia, and Remicade, research is showing Ozanimod to be a promising alternative IBD treatment option. Some of the available data compares Ozanimod to conventional anti-TNF treatments—in comparing Ozanimod's action of suppressing inflammatory cytokines and reducing lymphocytes, researchers have concluded that the new medication demonstrates robust efficacy when compared to conventional anti-TNF therapies.

In a Phase 2 study called the TOUCHSTONE study, researchers examined the effects of Ozanimod in approximately 200 patients with ulcerative colitis. At 8 months, the remission rate in the placebo group was 6%, while remission rates for patients taking Ozanimod were 21% and 26% (two groups taking different doses).

Find Your Treatment

See what treatments are right for you by answering a couple questions.

What condition do you have?

Crohn's Disease Ulcerative Colitis

Ozanimod Clinical Trials for IBD

Ozanimod entered into Phase 3 clinical trials for Crohn’s disease in early 2018 and is already in Phase 3 clinical trials for ulcerative colitis.

It is expected to first hit the market for multiple sclerosis in late 2018, with approval as an IBD treatment to follow.

Signing up for IBD Clinical Trials: Ozanimod

In Phase 3 clinical trials, a medication is already known to be well-tolerated and effective. Patients who participate in Phase 3 clinical trials for IBD treatments may be helping the researchers to measure the medication’s efficacy, dosing, and other other metrics.

Many patients who join clinical trials for Crohn’s disease or colitis have already tried several IBD treatment options with limited success. For these patients, joining a clinical trial can provide early access to innovative treatments, in addition to consultation with dedicated inflammatory bowel disease specialists.

Clinical Trials at the University of Chicago Medicine

At Discover Therapies, we connect IBD patients with clinical trials in various locations throughout North America, with many trials held at dedicated inflammatory bowel disease centres run by IBD specialists.

To determine your eligibility for clinical trials, sign up for Ozanimod, start by taking a short quiz on the Discover Therapies.

References

(2018). Ozanimod Successful in Clinical Trials for Multiple Sclerosis. The Scripps Research Institute. Retrieved from https://www.scripps.edu/news/press/2017/20171109ozanimod.html
Scott, F. L., Clemons, B., Brooks, J., Brahmachary, E., Powell, R., Dedman, H., … Peach, R. J. (2016). Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P1) and receptor‐5 (S1P5) agonist with autoimmune disease‐modifying activity. British Journal of Pharmacology, 173(11), 1778–1792. http://doi.org/10.1111/bph.13476
Tran, J. Q., Hartung, J. P., Peach, R. J., Boehm, M. F., Rosen, H., Smith, H., … Frohna, P. A. (2017). Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator. Journal of Clinical Pharmacology, 57(8), 988–996. http://doi.org/10.1002/jcph.887

Support

Sign up now and speak to a research coordinator